{"ticker": {"uuid": "2aaafabd-0dab-4867-8705-6d7f2bd5af95", "symbol": "FHTX", "name": "Foghorn Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(FHTX) Movement Within Algorithmic Entry Frameworks", "summary": "The article analyzes Foghorn Therapeutics Inc. (NASDAQ: FHTX) using algorithmic frameworks, noting conflicting sentiment across horizons and a mid-channel oscillation pattern. It presents three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014alon", "url": "https://news.stocktradersdaily.com/news_release/78/FHTX_Movement_Within_Algorithmic_Entry_Frameworks_071526091802_1784121482.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T09:11:21", "published_display": "15 Jul 2026 09:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Foghorn Therapeutics(FHTX) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQaVg4MXZLZjBpRkhXYWdtdndrNEcybldwS09sbDJMRWcwR3dKWkl6a1RDSE1wYmZQOW5lT3Jtak40YWt1dm5tWFlMRk1qVlotRWNRZXlLZzF1VC1ZRkdnOGthZnZicWNkVTBkTXhKUHFCdXRxNUU2bG80Zlh5NUpmOURFYkdGVjZnMlQ4M1RybHp6c3Y3X2VhdnFUZEN1Q1lTUW1uT1NmVEdyZUc2T2hjdkhjZWl6bkN3VFhEYzFDaEtiRk53Mlh3Q1M0YTd6M2hERDh3enJaUG9Ta3FqY09Hczd1WXczclBnaXBQdWg5Qjg5M2dEMTVESnRVZHN3dVVCVnZtVTM5anRvUFc2V3JiZ3JEZDRfRWVwV0F0elJrVUVPRlEwT1hXdg?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T08:23:09+00:00", "published_display": "13 Jul 2026 08:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $13", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSkZncTBMN2wyeF9NU3g1a1hBbWpVbm1NTXo4QUJraFRKTnJ0MlgyMUQ1cHl5bUdXSmh4SjhGSmZ2Q0dtMFl0ZmVRRHZZSDNIMmFMaEVKWW9zSFFTY0JpODFJRWhXcXM0WVlGSTV1Sy1uUE1NREFjZl9ndFJQS1NtTjNCRUlLQXctNFl2UXlkWWo0WmZTa0FmMkJJbS16SHpVYlowZmRzaWxpR2hUZXFMTmpiOF8tVGdJTEE?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-08T09:48:33+00:00", "published_display": "08 Jul 2026 09:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FHTX - Foghorn Therapeutics Inc Options", "summary": "This article provides comprehensive financial data for Foghorn Therapeutics Inc. (FHTX), including its last close price, market capitalization, key financial ratios, EPS and sales growth rates, insider and institutional ownership, and performance metrics over various periods. It ", "url": "https://finviz.com/stock?t=FHTX&p=d&r=m3&ty=oc&e=2026-07-17", "source_name": "Finviz", "published_at": "2026-07-06T14:11:24", "published_display": "06 Jul 2026 14:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FHTX - Foghorn Therapeutics Inc Dividends", "summary": "This article provides a comprehensive financial overview of Foghorn Therapeutics Inc. (FHTX), including its current stock performance, key financial metrics, insider and institutional ownership, and various performance indicators. It highlights the company's valuation, profitabil", "url": "https://finviz.com/stock?t=FHTX&p=d&ty=dv", "source_name": "Finviz", "published_at": "2026-07-04T05:39:50", "published_display": "04 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FHTX SEC Filings - Foghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Foghorn Therapeutics (FHTX) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights recent filings such as an investor presentation from September 2025 ", "url": "https://www.stocktitan.net/sec-filings/FHTX/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-03T22:10:20", "published_display": "03 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?", "summary": "Foghorn Therapeutics (FHTX) saw its shares jump 5.8% due to impressive trading volume and growing investor confidence linked to progress in its pipeline candidates for cancer treatments. The company is expected to report a quarterly loss of $0.23 per share and revenues of $8.12 m", "url": "https://finance.yahoo.com/markets/stocks/articles/foghorn-therapeutics-fhtx-surges-5-114200083.html", "source_name": "Market source", "published_at": "2026-07-03T12:10:12", "published_display": "03 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell 3000E Value Benchmark", "summary": "Foghorn Therapeutics Inc. (NasdaqGM:FHTX) has been removed from the Russell 3000E Value Benchmark, according to an update on June 28, 2026. This news follows several other index removals for the company, including the Russell 2000 Value and Russell Microcap Value Benchmarks aroun", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-3000e-value-benchmark-ce7f5fddda8df42d", "source_name": "marketscreener.com", "published_at": "2026-06-30T16:42:05", "published_display": "30 Jun 2026 16:42", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Benchmark Index", "summary": "Foghorn Therapeutics Inc. (NasdaqGM: FHTX) has been removed from the Russell Microcap Value Benchmark Index. The article also provides a company profile, financial data, analyst consensus, and a history of recent news related to Foghorn Therapeutics, including its presentations a", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdfd988f422", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:39:52", "published_display": "29 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 2000 Value Benchmark", "summary": "Foghorn Therapeutics Inc. (NasdaqGM: FHTX) has been removed from the Russell 2000 Value Benchmark Index. This news follows previous reports of the company presenting at the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026 and reporting its first-quarter earning", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-2000-value-benchmark-ce7f5fdfd88df224", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:26:00", "published_display": "29 Jun 2026 11:26", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Foghorn Therapeutics Inc. (NasdaqGM:FHTX) has been removed from the Russell Small Cap Comp Value Benchmark. This news follows several other announcements regarding the company's removal from various Russell indices, including the Russell 2000 Value, Russell Microcap Value, Russel", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdfd08cff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T00:13:08", "published_display": "29 Jun 2026 00:13", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 3000 Value Benchmark", "summary": "Foghorn Therapeutics Inc. (NasdaqGM: FHTX) has been removed from the Russell 3000 Value Benchmark, according to an announcement published on June 28, 2026. This exclusion follows its removal from several other Russell indices, including the Russell 2000 Value, Microcap Value, 300", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-3000-value-benchmark-ce7f5fdcd08ff72d", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T00:13:08", "published_display": "28 Jun 2026 00:13", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soft Tissue Sarcoma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings", "summary": "DelveInsight's \"Soft Tissue Sarcoma Pipeline Insight, 2026\" report highlights that over 70 companies are developing more than 75 therapies for Soft Tissue Sarcoma, covering various clinical development stages from pre-clinical to marketed phases. The report details emerging thera", "url": "https://www.barchart.com/story/news/18224/soft-tissue-sarcoma-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-oncotherapy-science-foghorn-therapeutics-c4-therapeutics-lyvgen-biopharma-holdings", "source_name": "Barchart.com", "published_at": "2026-06-27T11:41:00", "published_display": "27 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics, Inc. Actuals & Estimates (NASDAQ:FHTX)", "summary": "This article provides an overview of Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial results, such as recent earnings and revenue, upcoming earnings date, market cap", "url": "https://www.tradingview.com/symbols/NASDAQ-FHTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:42", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Foghorn Therapeutics Inc For: 25 June By Investing.com", "summary": "This article from Investing.com reports the filing of a Form 4 for Foghorn Therapeutics Inc. on June 25. A Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders, such as officers, directors, or beneficial owners, to report changes i", "url": "https://ng.investing.com/news/stock-market-news/form-4-foghorn-therapeuticsinc-for-25-june-93CH-2574776", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T22:40:53", "published_display": "25 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FHTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Foghorn Therapeutics Inc. (FHTX) stock, including analyst price targets, ratings, and financial performance data. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, ", "url": "https://www.tradingview.com/symbols/NASDAQ-FHTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:40:15", "published_display": "25 Jun 2026 22:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) director Lynne Parshall awarded 28,000 stock options", "summary": "Lynne Parshall, a director at Foghorn Therapeutics Inc. (FHTX), was granted 28,000 stock options with an exercise price of $4.08 per share, expiring on June 23, 2036. These options will fully vest on the first anniversary of the grant date, contingent on her continued service on ", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-760d4cf7e6e1.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:08", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) director granted 28,000 stock options at $4.08 strike", "summary": "Foghorn Therapeutics director Scott Biller was granted 28,000 stock options with an exercise price of $4.08 per share as compensation. These options will vest in full on the first anniversary of the grant date, provided he continues to serve on the board. Following this grant, Bi", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-77a4d6659007.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:08", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Foghorn Therapeutics (FHTX) receives 28,000 stock options", "summary": "Foghorn Therapeutics (FHTX) director Neil Gallagher was granted 28,000 stock options with an exercise price of $4.08 per share. These options are a compensation-related award and will vest in full on the first anniversary of the grant date, provided Gallagher continues his servic", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-e9b954231815.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:08", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) director receives stock options for 28,000 shares", "summary": "Foghorn Therapeutics director Thomas J. Lynch Jr. was granted stock options for 28,000 shares of common stock with an exercise price of $4.08 per share. These options are set to vest on the first anniversary of the grant date, conditional on his continued service on the board, an", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-3e805841b3e7.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:08", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Ian F. Smith receives 28,000 Foghorn Therapeutics (FHTX) stock options", "summary": "Foghorn Therapeutics Inc. director Ian F. Smith was granted 28,000 stock options at an exercise price of $4.08 per share. These options vest fully on the first anniversary of the grant date, contingent on his continued board service, and expire on June 23, 2036. This transaction ", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-8f0c63a0f264.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:07", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Foghorn (NASDAQ: FHTX) receives 28,000 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOdnNNUUkzRGNjM3dpYXA3eDg3Q2REUThwN0NYdjEzejFiSnlQMUJTM2lvZFZGczhQb2xpZkFIYm5LVEZKcGZ4ZnBpcE1NMmp4VjhSSE5nS2VQR21PRzI0YmpYenR2QzhHNjVPTHJsRHdQcDVfYk91UHdUcThmZjJ4dWJiNl9BcjV0S2hzaUV2cDRfNTRqaGRfcDZOakJfR1VjZ0tnVjZ2LTE4ZGh3cHFhSGNJLUFybWZDUEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) director Simba Gill granted 28,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNZmFJTzhFS0wtVzFIYkNQQVhlUzYwX1dkVHJaeUJLdUU1dUtmbGhmYmdGYUlDamVYM0NHZC1tWTRvcTJ0Znc0bDVXcXl4TmE3Qi1oam1NZHgwRURVZzJrRDJFa2QxaHRFNWVUOHR5QS1Ta2taYjFNQXJOVG44Mko1SFVTaEtSekFxV1FBWkg2REpUSWFROUNmWUUyZ1p4Mmw5djk3dElPdkVSam84aWRlTHh3TTV0RVVWMWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders at Foghorn Therapeutics (NASDAQ: FHTX) approve pay and auditor", "summary": "Foghorn Therapeutics Inc. shareholders approved key proposals at their 2026 Annual Meeting. They re-elected three Class III directors, ratified Deloitte & Touche LLP as the independent auditor for the 2026 fiscal year, and advisory-approved the compensation for named executive of", "url": "https://www.stocktitan.net/sec-filings/FHTX/8-k-foghorn-therapeutics-inc-reports-material-event-b3ce87f6d0b0.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:09:54", "published_display": "24 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) Edges Higher as Stock Holds Above Key Support - Low Volatility Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQSHgxa2FCWGxxTXZPWGJ3OG1TWUsxUDljTEYtbHhBOC1LSG1NbjlpbEt5TlVLbUZtQUxGdHYxT0VxbFpsT3NIZi02M0NET1UwMzBqb0dzVTdaZFhsT0pOYi1SaUF4NzBBZEpHTms0N1hCZUdmb1pYTnFsT1dVSGpPTFNTVmRkc2VORERGR1ZPS00xRUVjMWNQSXZiMzhpSVM0bThXYzByQ3l3eUZndjQtdU9tWQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Foghorn Therapeutics Inc. (FHTX) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends in the past five years and has no recorded stock split events. The page also includes current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fhtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:10:52", "published_display": "17 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article focuses on the revenue breakdown of Foghorn Therapeutics Inc. (FHTX) by business segments and regional contributions. However, it explicitly states that the relevant financial data for these categories has not been disclosed by the company yet. As a result, the artic", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fhtx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:10:52", "published_display": "17 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Foghorn Therapeutics Inc. (FHTX) currently holds an earnings forecast score of 9.00, placing it 14th in its industry, with an average analyst price target of $12.00, suggesting a significant upside. Ten analysts rate the stock as a \"Strong Buy.\" The company's expected revenue for", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fhtx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T13:10:32", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Foghorn Therapeutics Inc. (FHTX) by TradingKey, indicating a current valuation score of 8.06 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -3.44 and notes that relevant d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fhtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T18:10:32", "published_display": "16 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026", "summary": "Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company, announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Management, including President and CEO Adrian Gottschalk, will present a fireside chat on June 9, 202", "url": "https://finance.yahoo.com/sectors/healthcare/articles/foghorn-therapeutics-participate-goldman-sachs-110000145.html", "source_name": "Market source", "published_at": "2026-06-06T03:40:10", "published_display": "06 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Foghorn CEO to speak at Goldman Sachs global healthcare event", "summary": "Foghorn Therapeutics (Nasdaq:FHTX) announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. President and CEO Adrian Gottschalk will lead a fireside chat on June 9, 2026, at 1:20 p.m. EDT, and engage in one-on-one investor", "url": "https://www.stocktitan.net/news/FHTX/foghorn-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-13pn3a7yx3ye.html", "source_name": "Stock Titan", "published_at": "2026-06-05T11:09:22", "published_display": "05 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $12", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQXZWX3MzSnM5TEVka3pMZG1waEMtU2VkcEQ1ajIxdTc4VnFlTDg2bkJCNUVOUW8xT3N1VUszNkxJREtxdmdNSzg2SDVDVDVsaWdESnJCREJsMF84aDAzODI4TUJ0MFRJMDF5VU1rTkstS3h3UzRlYlpBMWZQLTRMdENuYXZiUWZGdW5iTDFTSWlOdlNDYTRKTDdGSWcyOEZCN09naXl0LTV4aE02c2xDbzFaX1VSb0xMaVlB?oc=5", "source_name": "Moomoo", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/foghorn-therapeutics-participate-three-upcoming-110000193.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRVJiYmZkVGFkQmpYd09pa3FNNEYxcUFraGpYQmNWektsTnZLeXh4emhNbnNZSmJMWmdMTlMxVmNPRzNqdGlPUDR5a0dYeWlTSnVVNEZpMGswcDdTS2FxNmh4NEdyS2NyUVg2YmtHd2hIRkdiYUtoUjEweE1Gb1lQd0JxMnY0WEx4VmZRcnNTOWNVbHpUQTV0eGhSWkFpRFNNczk4?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNdGFGMFJYWmw2VEdKVkdTV3hTWHU4bExjeDRVOVk1WFdfdFo2QVJPVm1pemxYOUswM3FPd29aQkVYQUVXV1p3dnBjQmNZOUdnYThLSVM4UnhrMkV0cG1hVDNheUJFMlRwX1AyUlNpaGdkcjdLaGRMU2hRRlVaeWhoSjhYbVRMUDJza3QwQ3N2dXJRRGpELXdCLXVtcG5RZ0JHdnc4M3hkWnQ2UHV5aU5SeG1FUjM5RmJnMEFuVDlUYkplSUFCeF9LWXBUUzJKODNsdTg1eF8wVnM5c2JCQ3RFNms0VEZnZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPNnBCbGIzTXowQTlDX0k0SjdEd2dYLWsyR191c2pjS2FUM1BsNm0wVzZDM1NwcVJ2bjhUTG04Z0RfTl9vMzd0MU9fSlZhckVGVGJpQmxHMmFYWmNybW0tZHFHck1FanVWVy04dmFFa3A0VkQ4TlZwTV9xTGZFamN4b1pFUWdOU21LT3lwMGFYSWNId0JzZVEtZkxSR1VWM2xpRnFaMnMxRjlQQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sarepta-therapeutics-srpt-q1-earnings-212508880.html", "source_name": "Zacks", "published_at": "2026-05-06T21:25:08+00:00", "published_display": "06 May 2026 21:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/foghorn-therapeutics-inc-fhtx-may-140005218.html", "source_name": "Zacks", "published_at": "2026-05-06T14:00:05+00:00", "published_display": "06 May 2026 14:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPblBaR0hLZ3lSSTdjZThTSWFuV3VkTkVRZ3ZJeWp2SXEyQWhnNmlrUmFiNlhNZWttaVZmc01tSDBWbmZnTlhXVVpsTmNfNWtTV25VR1lQekx6bzczeEZSQ0hwN3dsZ1BUNnRaTDl5MG01eFM3M2JPcVRmUWxBUzlVZDNrWHRoSThJdEJEQzlDRmVTQUlMSnJBenZIVVRka2NFcUFySl96bw?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPVEExYTRmZVJXNnZacWw3VWhXNG5BN2xoWHFJc01VQUNEMU9oaXpzR2lNZEFnSkhYbFNiOHcteGlKRnRUY1BXeXl2ZWgyZWNBdjU5RVhiMjNFTUNsakJhX0gtSUtOUkIwZG5pN1FmSDBkMlU2U1NhWVB6anBNYTVDNUh1MXNEZw?oc=5", "source_name": "Market source", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPZk15Znk2cDZrTjNEaEd5WjN1N0dJVmFGVWJ0N0VOeVZLd1VnTlM2QlJZV3BiaXlYUDktQ3h0UHZ3ZDJLQ2kzc08wVzJwZG1RWG1FZWZqRFUxM2dDcEpsTzExSS1jd1AyNF81NVNJRi0wVjYzM1VmSFhLZVVPSlRFTzVNSDZDWk1SdmZXWlZ5MzJoQ0prX0xtbk5hYnY2aF92MjFIN3Z3Q1NTOVhUNVpoMTFTLVB1NHljNkttanZmQ0dod2RQWF9zRmcxS3hWQlU?oc=5", "source_name": "Investing News Network", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs - Slideshow (NASDAQ:FHTX) 2025-10-30", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPR0tkMktJY0FTWXpVUl92bEVNaFlzR1hHMWJyb0VIZFBfYlNzY2tqbXZFajllVlh2dGtrQkVWRFMxcEJYenYzdFFraV9heGhMenhvaGVnU2pOMDByY00yT2cwdGphdXlUVUM5WkpGUlBGZU1wcHNDLTcybXF4b0FWbHdBRFBVSXlCUVZ1bWY2Z3RQM1dKV0xQcjhOdGJxSzdjSlRncEdoN2NuZWZyYUdSSVQ2RURWckhfYXk2OTFXVDQwVnFNWTZNdk9udXM?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA1Y00tblE5N3pzWEJicXdHYmNNeGF6UU45NFp3XzFmem9YRWNicmI4Ty11ZGY4cXpmV0JRd19FNzFqX1pOT21FUXNHd19jOWpMNklj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T21:20:27+00:00", "published_display": "24 Apr 2025 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5FY2JZaVFtT19UWTJ6Tnp2VmVEMlFOX0xNVjAwampOendYVHRja2JIUjVMb2g2Ull5MFE3YjRHU2x2RUpyUW8zQ2ZXM3B0ZVBqN2Rn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T20:45:36+00:00", "published_display": "24 Apr 2025 20:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1fMFdwci03TGpaTC1WRUNsWVVEZHNKR0dBWGs1TDhWNmRvSzZZWWVtWWE5S0JBd0hXS1dqTnN0ZFJ4c1JmVThSQmVJaW1ta3htbUtkRGxpQzI0blNVSWdtR0FmRU92Zw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:36:53+00:00", "published_display": "11 May 2024 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly steers into Foghorn\u2019s gene traffic control drugs with $380M pact in cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNdVZ0WTVLSEY1ZVJhRm56dy1LZWVTTks5WmRKSWo1WjFxVFp3M2YxcFVoUHBJT1ZtSFp3T3BzZFV5dHZza3lGNzNFelgxcEpIWU0wc0pBWkViVGQ4YWJEbkUySTE1SG1rZWpXVEtGbzMxanZYbnRMSDZhNDhLeTg0dm0zeG9XVXRzbjdaZ24wZkVjb0ZWdmo5RGRLOVFCMGlOTm5yREEtV2g5QUd2eGNaanBoV0pGUQ?oc=5", "source_name": "MedCity News", "published_at": "2021-12-13T08:00:00+00:00", "published_display": "13 Dec 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "(FHTX) Movement Within Algorithmic Entry Frameworks", "summary": "The article analyzes Foghorn Therapeutics Inc. (NASDAQ: FHTX) using algorithmic frameworks, noting conflicting sentiment across horizons and a mid-channel oscillation pattern. It presents three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014alon", "url": "https://news.stocktradersdaily.com/news_release/78/FHTX_Movement_Within_Algorithmic_Entry_Frameworks_071526091802_1784121482.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T09:11:21", "published_display": "15 Jul 2026 09:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics(FHTX) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQaVg4MXZLZjBpRkhXYWdtdndrNEcybldwS09sbDJMRWcwR3dKWkl6a1RDSE1wYmZQOW5lT3Jtak40YWt1dm5tWFlMRk1qVlotRWNRZXlLZzF1VC1ZRkdnOGthZnZicWNkVTBkTXhKUHFCdXRxNUU2bG80Zlh5NUpmOURFYkdGVjZnMlQ4M1RybHp6c3Y3X2VhdnFUZEN1Q1lTUW1uT1NmVEdyZUc2T2hjdkhjZWl6bkN3VFhEYzFDaEtiRk53Mlh3Q1M0YTd6M2hERDh3enJaUG9Ta3FqY09Hczd1WXczclBnaXBQdWg5Qjg5M2dEMTVESnRVZHN3dVVCVnZtVTM5anRvUFc2V3JiZ3JEZDRfRWVwV0F0elJrVUVPRlEwT1hXdg?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T08:23:09+00:00", "published_display": "13 Jul 2026 08:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $13", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSkZncTBMN2wyeF9NU3g1a1hBbWpVbm1NTXo4QUJraFRKTnJ0MlgyMUQ1cHl5bUdXSmh4SjhGSmZ2Q0dtMFl0ZmVRRHZZSDNIMmFMaEVKWW9zSFFTY0JpODFJRWhXcXM0WVlGSTV1Sy1uUE1NREFjZl9ndFJQS1NtTjNCRUlLQXctNFl2UXlkWWo0WmZTa0FmMkJJbS16SHpVYlowZmRzaWxpR2hUZXFMTmpiOF8tVGdJTEE?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-08T09:48:33+00:00", "published_display": "08 Jul 2026 09:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FHTX - Foghorn Therapeutics Inc Options", "summary": "This article provides comprehensive financial data for Foghorn Therapeutics Inc. (FHTX), including its last close price, market capitalization, key financial ratios, EPS and sales growth rates, insider and institutional ownership, and performance metrics over various periods. It ", "url": "https://finviz.com/stock?t=FHTX&p=d&r=m3&ty=oc&e=2026-07-17", "source_name": "Finviz", "published_at": "2026-07-06T14:11:24", "published_display": "06 Jul 2026 14:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FHTX - Foghorn Therapeutics Inc Dividends", "summary": "This article provides a comprehensive financial overview of Foghorn Therapeutics Inc. (FHTX), including its current stock performance, key financial metrics, insider and institutional ownership, and various performance indicators. It highlights the company's valuation, profitabil", "url": "https://finviz.com/stock?t=FHTX&p=d&ty=dv", "source_name": "Finviz", "published_at": "2026-07-04T05:39:50", "published_display": "04 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FHTX SEC Filings - Foghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Foghorn Therapeutics (FHTX) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights recent filings such as an investor presentation from September 2025 ", "url": "https://www.stocktitan.net/sec-filings/FHTX/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-03T22:10:20", "published_display": "03 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?", "summary": "Foghorn Therapeutics (FHTX) saw its shares jump 5.8% due to impressive trading volume and growing investor confidence linked to progress in its pipeline candidates for cancer treatments. The company is expected to report a quarterly loss of $0.23 per share and revenues of $8.12 m", "url": "https://finance.yahoo.com/markets/stocks/articles/foghorn-therapeutics-fhtx-surges-5-114200083.html", "source_name": "Market source", "published_at": "2026-07-03T12:10:12", "published_display": "03 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell 3000E Value Benchmark", "summary": "Foghorn Therapeutics Inc. (NasdaqGM:FHTX) has been removed from the Russell 3000E Value Benchmark, according to an update on June 28, 2026. This news follows several other index removals for the company, including the Russell 2000 Value and Russell Microcap Value Benchmarks aroun", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-3000e-value-benchmark-ce7f5fddda8df42d", "source_name": "marketscreener.com", "published_at": "2026-06-30T16:42:05", "published_display": "30 Jun 2026 16:42", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Benchmark Index", "summary": "Foghorn Therapeutics Inc. (NasdaqGM: FHTX) has been removed from the Russell Microcap Value Benchmark Index. The article also provides a company profile, financial data, analyst consensus, and a history of recent news related to Foghorn Therapeutics, including its presentations a", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdfd988f422", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:39:52", "published_display": "29 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 2000 Value Benchmark", "summary": "Foghorn Therapeutics Inc. (NasdaqGM: FHTX) has been removed from the Russell 2000 Value Benchmark Index. This news follows previous reports of the company presenting at the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026 and reporting its first-quarter earning", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-2000-value-benchmark-ce7f5fdfd88df224", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:26:00", "published_display": "29 Jun 2026 11:26", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Foghorn Therapeutics Inc. (NasdaqGM:FHTX) has been removed from the Russell Small Cap Comp Value Benchmark. This news follows several other announcements regarding the company's removal from various Russell indices, including the Russell 2000 Value, Russell Microcap Value, Russel", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdfd08cff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T00:13:08", "published_display": "29 Jun 2026 00:13", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 3000 Value Benchmark", "summary": "Foghorn Therapeutics Inc. (NasdaqGM: FHTX) has been removed from the Russell 3000 Value Benchmark, according to an announcement published on June 28, 2026. This exclusion follows its removal from several other Russell indices, including the Russell 2000 Value, Microcap Value, 300", "url": "https://www.marketscreener.com/news/foghorn-therapeutics-inc-nasdaqgm-fhtx-dropped-from-russell-3000-value-benchmark-ce7f5fdcd08ff72d", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T00:13:08", "published_display": "28 Jun 2026 00:13", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soft Tissue Sarcoma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings", "summary": "DelveInsight's \"Soft Tissue Sarcoma Pipeline Insight, 2026\" report highlights that over 70 companies are developing more than 75 therapies for Soft Tissue Sarcoma, covering various clinical development stages from pre-clinical to marketed phases. The report details emerging thera", "url": "https://www.barchart.com/story/news/18224/soft-tissue-sarcoma-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-oncotherapy-science-foghorn-therapeutics-c4-therapeutics-lyvgen-biopharma-holdings", "source_name": "Barchart.com", "published_at": "2026-06-27T11:41:00", "published_display": "27 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics, Inc. Actuals & Estimates (NASDAQ:FHTX)", "summary": "This article provides an overview of Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial results, such as recent earnings and revenue, upcoming earnings date, market cap", "url": "https://www.tradingview.com/symbols/NASDAQ-FHTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:42", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Foghorn Therapeutics Inc For: 25 June By Investing.com", "summary": "This article from Investing.com reports the filing of a Form 4 for Foghorn Therapeutics Inc. on June 25. A Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders, such as officers, directors, or beneficial owners, to report changes i", "url": "https://ng.investing.com/news/stock-market-news/form-4-foghorn-therapeuticsinc-for-25-june-93CH-2574776", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T22:40:53", "published_display": "25 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FHTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Foghorn Therapeutics Inc. (FHTX) stock, including analyst price targets, ratings, and financial performance data. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, ", "url": "https://www.tradingview.com/symbols/NASDAQ-FHTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:40:15", "published_display": "25 Jun 2026 22:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) director Lynne Parshall awarded 28,000 stock options", "summary": "Lynne Parshall, a director at Foghorn Therapeutics Inc. (FHTX), was granted 28,000 stock options with an exercise price of $4.08 per share, expiring on June 23, 2036. These options will fully vest on the first anniversary of the grant date, contingent on her continued service on ", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-760d4cf7e6e1.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:08", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) director granted 28,000 stock options at $4.08 strike", "summary": "Foghorn Therapeutics director Scott Biller was granted 28,000 stock options with an exercise price of $4.08 per share as compensation. These options will vest in full on the first anniversary of the grant date, provided he continues to serve on the board. Following this grant, Bi", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-77a4d6659007.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:08", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Foghorn Therapeutics (FHTX) receives 28,000 stock options", "summary": "Foghorn Therapeutics (FHTX) director Neil Gallagher was granted 28,000 stock options with an exercise price of $4.08 per share. These options are a compensation-related award and will vest in full on the first anniversary of the grant date, provided Gallagher continues his servic", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-e9b954231815.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:08", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) director receives stock options for 28,000 shares", "summary": "Foghorn Therapeutics director Thomas J. Lynch Jr. was granted stock options for 28,000 shares of common stock with an exercise price of $4.08 per share. These options are set to vest on the first anniversary of the grant date, conditional on his continued service on the board, an", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-3e805841b3e7.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:08", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Ian F. Smith receives 28,000 Foghorn Therapeutics (FHTX) stock options", "summary": "Foghorn Therapeutics Inc. director Ian F. Smith was granted 28,000 stock options at an exercise price of $4.08 per share. These options vest fully on the first anniversary of the grant date, contingent on his continued board service, and expire on June 23, 2036. This transaction ", "url": "https://www.stocktitan.net/sec-filings/FHTX/form-4-foghorn-therapeutics-inc-insider-trading-activity-8f0c63a0f264.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:40:07", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Foghorn (NASDAQ: FHTX) receives 28,000 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOdnNNUUkzRGNjM3dpYXA3eDg3Q2REUThwN0NYdjEzejFiSnlQMUJTM2lvZFZGczhQb2xpZkFIYm5LVEZKcGZ4ZnBpcE1NMmp4VjhSSE5nS2VQR21PRzI0YmpYenR2QzhHNjVPTHJsRHdQcDVfYk91UHdUcThmZjJ4dWJiNl9BcjV0S2hzaUV2cDRfNTRqaGRfcDZOakJfR1VjZ0tnVjZ2LTE4ZGh3cHFhSGNJLUFybWZDUEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) director Simba Gill granted 28,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNZmFJTzhFS0wtVzFIYkNQQVhlUzYwX1dkVHJaeUJLdUU1dUtmbGhmYmdGYUlDamVYM0NHZC1tWTRvcTJ0Znc0bDVXcXl4TmE3Qi1oam1NZHgwRURVZzJrRDJFa2QxaHRFNWVUOHR5QS1Ta2taYjFNQXJOVG44Mko1SFVTaEtSekFxV1FBWkg2REpUSWFROUNmWUUyZ1p4Mmw5djk3dElPdkVSam84aWRlTHh3TTV0RVVWMWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders at Foghorn Therapeutics (NASDAQ: FHTX) approve pay and auditor", "summary": "Foghorn Therapeutics Inc. shareholders approved key proposals at their 2026 Annual Meeting. They re-elected three Class III directors, ratified Deloitte & Touche LLP as the independent auditor for the 2026 fiscal year, and advisory-approved the compensation for named executive of", "url": "https://www.stocktitan.net/sec-filings/FHTX/8-k-foghorn-therapeutics-inc-reports-material-event-b3ce87f6d0b0.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:09:54", "published_display": "24 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) Edges Higher as Stock Holds Above Key Support - Low Volatility Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQSHgxa2FCWGxxTXZPWGJ3OG1TWUsxUDljTEYtbHhBOC1LSG1NbjlpbEt5TlVLbUZtQUxGdHYxT0VxbFpsT3NIZi02M0NET1UwMzBqb0dzVTdaZFhsT0pOYi1SaUF4NzBBZEpHTms0N1hCZUdmb1pYTnFsT1dVSGpPTFNTVmRkc2VORERGR1ZPS00xRUVjMWNQSXZiMzhpSVM0bThXYzByQ3l3eUZndjQtdU9tWQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Foghorn Therapeutics Inc. (FHTX) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends in the past five years and has no recorded stock split events. The page also includes current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fhtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:10:52", "published_display": "17 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article focuses on the revenue breakdown of Foghorn Therapeutics Inc. (FHTX) by business segments and regional contributions. However, it explicitly states that the relevant financial data for these categories has not been disclosed by the company yet. As a result, the artic", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fhtx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:10:52", "published_display": "17 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Foghorn Therapeutics Inc. (FHTX) currently holds an earnings forecast score of 9.00, placing it 14th in its industry, with an average analyst price target of $12.00, suggesting a significant upside. Ten analysts rate the stock as a \"Strong Buy.\" The company's expected revenue for", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fhtx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T13:10:32", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Foghorn Therapeutics Inc. (FHTX) by TradingKey, indicating a current valuation score of 8.06 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -3.44 and notes that relevant d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fhtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T18:10:32", "published_display": "16 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026", "summary": "Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company, announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Management, including President and CEO Adrian Gottschalk, will present a fireside chat on June 9, 202", "url": "https://finance.yahoo.com/sectors/healthcare/articles/foghorn-therapeutics-participate-goldman-sachs-110000145.html", "source_name": "Market source", "published_at": "2026-06-06T03:40:10", "published_display": "06 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Foghorn CEO to speak at Goldman Sachs global healthcare event", "summary": "Foghorn Therapeutics (Nasdaq:FHTX) announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. President and CEO Adrian Gottschalk will lead a fireside chat on June 9, 2026, at 1:20 p.m. EDT, and engage in one-on-one investor", "url": "https://www.stocktitan.net/news/FHTX/foghorn-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-13pn3a7yx3ye.html", "source_name": "Stock Titan", "published_at": "2026-06-05T11:09:22", "published_display": "05 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $12", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQXZWX3MzSnM5TEVka3pMZG1waEMtU2VkcEQ1ajIxdTc4VnFlTDg2bkJCNUVOUW8xT3N1VUszNkxJREtxdmdNSzg2SDVDVDVsaWdESnJCREJsMF84aDAzODI4TUJ0MFRJMDF5VU1rTkstS3h3UzRlYlpBMWZQLTRMdENuYXZiUWZGdW5iTDFTSWlOdlNDYTRKTDdGSWcyOEZCN09naXl0LTV4aE02c2xDbzFaX1VSb0xMaVlB?oc=5", "source_name": "Moomoo", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/foghorn-therapeutics-participate-three-upcoming-110000193.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRVJiYmZkVGFkQmpYd09pa3FNNEYxcUFraGpYQmNWektsTnZLeXh4emhNbnNZSmJMWmdMTlMxVmNPRzNqdGlPUDR5a0dYeWlTSnVVNEZpMGswcDdTS2FxNmh4NEdyS2NyUVg2YmtHd2hIRkdiYUtoUjEweE1Gb1lQd0JxMnY0WEx4VmZRcnNTOWNVbHpUQTV0eGhSWkFpRFNNczk4?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNdGFGMFJYWmw2VEdKVkdTV3hTWHU4bExjeDRVOVk1WFdfdFo2QVJPVm1pemxYOUswM3FPd29aQkVYQUVXV1p3dnBjQmNZOUdnYThLSVM4UnhrMkV0cG1hVDNheUJFMlRwX1AyUlNpaGdkcjdLaGRMU2hRRlVaeWhoSjhYbVRMUDJza3QwQ3N2dXJRRGpELXdCLXVtcG5RZ0JHdnc4M3hkWnQ2UHV5aU5SeG1FUjM5RmJnMEFuVDlUYkplSUFCeF9LWXBUUzJKODNsdTg1eF8wVnM5c2JCQ3RFNms0VEZnZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPNnBCbGIzTXowQTlDX0k0SjdEd2dYLWsyR191c2pjS2FUM1BsNm0wVzZDM1NwcVJ2bjhUTG04Z0RfTl9vMzd0MU9fSlZhckVGVGJpQmxHMmFYWmNybW0tZHFHck1FanVWVy04dmFFa3A0VkQ4TlZwTV9xTGZFamN4b1pFUWdOU21LT3lwMGFYSWNId0JzZVEtZkxSR1VWM2xpRnFaMnMxRjlQQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sarepta-therapeutics-srpt-q1-earnings-212508880.html", "source_name": "Zacks", "published_at": "2026-05-06T21:25:08+00:00", "published_display": "06 May 2026 21:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/foghorn-therapeutics-inc-fhtx-may-140005218.html", "source_name": "Zacks", "published_at": "2026-05-06T14:00:05+00:00", "published_display": "06 May 2026 14:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPblBaR0hLZ3lSSTdjZThTSWFuV3VkTkVRZ3ZJeWp2SXEyQWhnNmlrUmFiNlhNZWttaVZmc01tSDBWbmZnTlhXVVpsTmNfNWtTV25VR1lQekx6bzczeEZSQ0hwN3dsZ1BUNnRaTDl5MG01eFM3M2JPcVRmUWxBUzlVZDNrWHRoSThJdEJEQzlDRmVTQUlMSnJBenZIVVRka2NFcUFySl96bw?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPVEExYTRmZVJXNnZacWw3VWhXNG5BN2xoWHFJc01VQUNEMU9oaXpzR2lNZEFnSkhYbFNiOHcteGlKRnRUY1BXeXl2ZWgyZWNBdjU5RVhiMjNFTUNsakJhX0gtSUtOUkIwZG5pN1FmSDBkMlU2U1NhWVB6anBNYTVDNUh1MXNEZw?oc=5", "source_name": "Market source", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPZk15Znk2cDZrTjNEaEd5WjN1N0dJVmFGVWJ0N0VOeVZLd1VnTlM2QlJZV3BiaXlYUDktQ3h0UHZ3ZDJLQ2kzc08wVzJwZG1RWG1FZWZqRFUxM2dDcEpsTzExSS1jd1AyNF81NVNJRi0wVjYzM1VmSFhLZVVPSlRFTzVNSDZDWk1SdmZXWlZ5MzJoQ0prX0xtbk5hYnY2aF92MjFIN3Z3Q1NTOVhUNVpoMTFTLVB1NHljNkttanZmQ0dod2RQWF9zRmcxS3hWQlU?oc=5", "source_name": "Investing News Network", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs - Slideshow (NASDAQ:FHTX) 2025-10-30", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPR0tkMktJY0FTWXpVUl92bEVNaFlzR1hHMWJyb0VIZFBfYlNzY2tqbXZFajllVlh2dGtrQkVWRFMxcEJYenYzdFFraV9heGhMenhvaGVnU2pOMDByY00yT2cwdGphdXlUVUM5WkpGUlBGZU1wcHNDLTcybXF4b0FWbHdBRFBVSXlCUVZ1bWY2Z3RQM1dKV0xQcjhOdGJxSzdjSlRncEdoN2NuZWZyYUdSSVQ2RURWckhfYXk2OTFXVDQwVnFNWTZNdk9udXM?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA1Y00tblE5N3pzWEJicXdHYmNNeGF6UU45NFp3XzFmem9YRWNicmI4Ty11ZGY4cXpmV0JRd19FNzFqX1pOT21FUXNHd19jOWpMNklj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T21:20:27+00:00", "published_display": "24 Apr 2025 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5FY2JZaVFtT19UWTJ6Tnp2VmVEMlFOX0xNVjAwampOendYVHRja2JIUjVMb2g2Ull5MFE3YjRHU2x2RUpyUW8zQ2ZXM3B0ZVBqN2Rn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T20:45:36+00:00", "published_display": "24 Apr 2025 20:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Foghorn Therapeutics (FHTX) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1fMFdwci03TGpaTC1WRUNsWVVEZHNKR0dBWGs1TDhWNmRvSzZZWWVtWWE5S0JBd0hXS1dqTnN0ZFJ4c1JmVThSQmVJaW1ta3htbUtkRGxpQzI0blNVSWdtR0FmRU92Zw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T13:36:53+00:00", "published_display": "11 May 2024 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly steers into Foghorn\u2019s gene traffic control drugs with $380M pact in cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNdVZ0WTVLSEY1ZVJhRm56dy1LZWVTTks5WmRKSWo1WjFxVFp3M2YxcFVoUHBJT1ZtSFp3T3BzZFV5dHZza3lGNzNFelgxcEpIWU0wc0pBWkViVGQ4YWJEbkUySTE1SG1rZWpXVEtGbzMxanZYbnRMSDZhNDhLeTg0dm0zeG9XVXRzbjdaZ24wZkVjb0ZWdmo5RGRLOVFCMGlOTm5yREEtV2g5QUd2eGNaanBoV0pGUQ?oc=5", "source_name": "MedCity News", "published_at": "2021-12-13T08:00:00+00:00", "published_display": "13 Dec 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 57, "sentiment_summary": {"positive": 7, "negative": 13, "neutral": 37, "score": 48, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.85, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 10.46, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 13}, "market_context": {"has_market_context": true, "latest_close": 5.95, "latest_week": "2026-07-10", "one_week_move": 12.3, "four_week_move": 42.3, "twelve_week_move": 12.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.33028, "market_dynamics_buy_signal": false, "relative_strength": 2.452622, "fair_value_gap": 7.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 45.1695, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+12.3% over one week, +42.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 12}, {"label": "www.marketscreener.com", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 4}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+12.3% over one week, +42.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "(FHTX) Movement Within Algorithmic Entry Frameworks"}], "updated_at": "2026-07-18T02:55:25.777764+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}